HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases.

Abstract
The proprotein convertases (PCs) are responsible for the endoproteolytic processing of various protein precursors (e.g., growth factors, receptors, adhesion molecules, and matrix metalloproteinases) implicated in several diseases such as obesity, diabetes, atherosclerosis, cancer, and Alzheimer disease. The potential clinical and pharmacological role of the PCs has fostered the development of various PC-inhibitors. In this review we summarized the recent findings on PCs inhibitors, their mode of actions and potential use in the therapy of various diseases.
AuthorsYannick Bontemps, Nathalie Scamuffa, Fabien Calvo, Abdel-Majid Khatib
JournalMedicinal research reviews (Med Res Rev) Vol. 27 Issue 5 Pg. 631-48 (Sep 2007) ISSN: 0198-6325 [Print] United States
PMID17019676 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright(c) 2006 Wiley Periodicals, Inc.
Chemical References
  • Protease Inhibitors
  • Proprotein Convertases
Topics
  • Humans
  • Models, Biological
  • Models, Molecular
  • Proprotein Convertases (antagonists & inhibitors, metabolism)
  • Protease Inhibitors (chemistry, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: